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Background: The objective of this study was to determine the in vitro tumor-inhibitory effect of a recombinant
adenovirus expressing a fusion protein of tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL) and
hemagglutinin-neuraminidase (HN) genes on the MSB-1 Marek’s disease tumor cell line.
Methods: TRAIL and HN genes were amplified from lymphocytes in the peripheral blood of chickens and the
LaSota strain of Newcastle disease virus (NDV), respectively, using RT-PCR. The two genes were connected with a
2A connecting peptide by site-directed mutagenesis and gene splicing by overlap extension (SOE). The target gene
TRAIL-2A-HN was cloned into the shuttle vector pShuttle-CMV. Homologous recombination was carried out with
the vector pAdeasy-1 in the bacterium BJ5183 to construct the recombinant adenovirus plasmid pAd-TRAIL-2A-HN.
After linearization, the plasmid was transfected into AD293 cells and packaged. Real-time quantitative PCR (RT-PCR)
and fluorescence microscopy confirmed the introduction of the recombinant adenovirus into AD293 cells. The
TCID50 method (50% tissue culture infectious dose) was employed to determine viral titers for the exprimental and
control viruses, which met criteria for use. The Marek’s disease tumor cell line MSB-1 was transfected with the constructed
recombinant adenovirus. The infectivity of the recombinant adenovirus and the expression levels of exogenous genes were
detected with RT-PCR and western blotting. The effects of the recombinant adenovirus on the growth of MSB-1 cells and
cellular apoptosis were determined using flow cytometry.
Results: The recombinant adenovirus infected the cultured cells in vitro, and replicated and expressed exogenous genes in
the cells. The recombinant adenovirus Ad-TRAIL-2A-HN inhibited the growth of MSB-1 cells and induced apoptosis
by expressing exogenous genes. The rate of induced MSB-1 cell apoptosis reached 11.61%, which indicated that
TRAIL and HN produced synergistic tumor-inhibiting effects.
Conclusion: The constructed TRAIL-2A-HN fusion gene combined the apoptosis-inducing function of TRAIL and
the adsorptive capacity of HN from NDV for tumor cells, and the capacity of the recombinant adenovirus expressing
this fusion gene to induce tumor cell apoptosis was reported. These results provide a basis for future in vivo tumor
suppression studies using recombinant adenoviruses.
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Marek’s disease (MD) is a lymphoproliferative infectious
disease in chickens that is caused by the Marek’s disease
virus (MDV). Since the first report of MD by Joseph
Marek in 1907, the pathogenicity of MDV has pro-
gressed from moderate virulence (mMDV), to strong
virulence (vMDV), to very strong virulence (vvMDV). At
the beginning of the 1980s, a mutant with super strong
virulence (vv +MDV) appeared [1]. This disease is com-
mon in poultry farms with intensive and condensed rear-
ing, and it is one of the major neoplastic diseases
endangering poultry breeding. Clinically, MD is generally
prevented and controlled by vaccination. However, sig-
nificant technical issues remain with regard to the pre-
vention and control of neoplastic diseases. Emerging
gene testing and therapy methods have provided new
strategies for the treatment of neoplastic diseases that
solve some of these issues.
In gene therapy, external normal genes are introduced
into the target cells to rectify or compensate for the effects
of genetic defects and abnormalities and achieve therapeutic
goals. Currently, adenovirus (Ad) is used as the vector
through which external genes are introduced in 40% of clin-
ical tests related to gene therapy. Gene therapy using adeno-
virus vectors is one of the most promising gene transfer
methods in gene therapy, and this method has shown non-
toxicity and non-diffusibility in animal tests [2]. The success-
ful construction of human adenovirus (i.e. Ad5) vectors and
their clinical application has resulted in the adenovirus be-
coming the most common means through which thera-
peutic genes are introduced into target cells [3,4].
Tumor necrosis factor (TNF) related apoptosis indu-
cing ligand (TRAIL), or Apo2 ligand (Apo2L), is a mem-
ber of the TNF super-family cloned from the cDNA
library of human myocardium by Wiley et al. in 1995
[5], which shows high homology with Fas ligand (FasL).
It is so named because its amino acid sequence has the
predicted structural characteristics of the TNF super-
family and it can induce apoptosis in human lympho-
cytes transformed by Jurkat cells and EB viruses.
TRAIL can selectively kill tumor cells in a manner that
is minimally virulent to most normal cells. Therefore, it
is a focus of tumor treatment research. Some researchers
have achieved tumor cell apoptosis by promoting or en-
hancing TRAIL expression in tumor cells. In these stud-
ies, adenovirus recombinant vectors carrying a gene for
functional TRAIL were constructed and introduced into
tumors such as human renal carcinoma [6], breast car-
cinoma [7], hepatic carcinoma [8], and squamous carcin-
oma [9], in which the functional TRAIL protein was
continuously expressed to inhibit tumor growth.
Cassel et al. showed in 1965 that the outbreak of
Newcastle disease (ND) inhibited metastasis in patients
with advanced gastric carcinoma [10]. After this report,more attention was focused on the anti-tumor effect of
Newcastle disease virus (NDV), and research of this type is
currently in the clinical stage. Hemagglutinin-neuraminidase
(HN) is the primary component of the large spike glycopro-
tein on the NDV envelopes, has a length of 1734 bp (encod-
ing 577 amino acids) and a molecular weight of 63 kD, and
can control hemagglutinin and neuraminidase activity.
Hemagglutinin is responsible for recognizing the sialic
acid-containing receptors of permissive cells. Neur-
aminidase can hydrolyze sialic acid on the surface of
host cells, decompose sialic acid-containing receptors,
expose the biological recognition sites of host cells, pro-
mote the release of new virus particles from the infected
cell membrane, and finally induce TRAIL expression by
mononuclear lymphocytes in the peripheral blood [2,11,12].
To enhance the inhibitory effect of TRAIL on MD tumor
cells, it was introduced in combination with HN in this
experiment.
The TRAIL and HN genes were amplified from the
lymphocytes in the peripheral blood of chickens and the
NDV (LaSota lentogenic strain), respectively. A recom-
binant adenovirus (Ad-TRAIL-2A-HN) with a fusion
protein of the above genes was constructed to take ad-
vantage of the targetability of TRAIL to tumor cells, the
apoptosis-inducing effect of HN, and the efficient and
stable expression of exogenous genes by adenovirus. The
in vitro inhibitory effect of Ad-TRAIL-2A-HN on Marek’s
disease tumor cell line MSB-1 was evaluated to explore
the ability of recombinant adenoviruses to induce apop-
tosis of MSB-1 tumor cells and thus their potential use in
clinical gene therapy.
Results
PCR identification of TRAIL, HN, and TRAIL-2A-HN
Using PCR, 915 bp of the TRAIL gene and 1716 bp of
the HN gene were amplified. The TRAIL gene and HN
gene were connected with a 2A connecting peptide by
SOE, and 2691 bp of the TRAIL-2A-HN fusion gene
was amplified, which conformed to the expected result
(Figure 1).
Enzyme digestion of recombinant adenovirus plasmids
After PacI enzyme digestion of pAd-TRAIL, pAd-HN,
pAd-TRAIL-2A-HN, and pAd-GFP, fragments of 3 kb,
4.5 kb, 4.5 kb, and 3 kb were obtained, respectively
(Figure 2), indicating that the homologous recombin-
ation of pAd-TRAIL and pAd-GFP occurred on the left
arm, and that of pAd-HN and pAd-TRAIL-2A-HN oc-
curred at the origin of replication.
Packaging of adenoviruses and TCID50 detection
AD293 cells were cultured by routine methods. When cells
in good condition occupied 80%–90% of the culture dish,
the recombinant adenovirus plasmids pAd-TRAIL-2A-HN,
Figure 1 PCR Amplification results for TRAIL, HN, and the
TRAIL-2A-HN fusion gene. M1: DL15000 DNA Marker; 1: SOE
product of TRAIL-2A-HN fusion gene; 2: PCR product of TRAIL gene;
3: PCR product of HN gene; M2: DL2000 DNA Marker.
Figure 2 Identification of recombinant adenoviral plasmids by
enzyme digestion. M: DL15000 DNA Marker; 1: pAd-TRAIL digested
by PacI; 2: pAd-HN digested by PacI; 3: pAd-TRAIL-2A-HN digested
by PacI; 4: pAd-GFP digested by PacI.
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the AD293 cells. After 7 days, the cells showed pathological
changes indicative of a typical cytopathic effect (CPE):
the cells became round and karyopyknosis occurred (see
Figure 3). The obtained viruses were named Ad-TRAIL-
2A-HN, Ad-TRAIL, Ad-HN, and Ad-GFP.
AD293 cells in good condition were inoculated with the
viruses, and cellular lesions appeared on the 6th day after
inoculation. After purification, the TCID50 values of the
Ad-TRAIL-2A-HN, Ad-TRAIL, Ad-HN, and Ad-GFP were
determined to be 109.17 TCID50/mL, 10
9.50 TCID50/mL,
109.83 TCID50/mL, and 10
9.50 TCID50/mL, respectively.
Transfection of MSB-1 cells with recombinant adenovirus
and detection of target genes and expressed products
MSB-1 cells were transfected with Ad-TRAIL, Ad-HN,
Ad-GFP, or Ad-TRAIL-2A-HN. After 48 h, the cellswere collected and mRNA for target genes was detected
with RT-PCR. Results (Figure 4) showed obvious products
of 915 bp, 1716 bp, and 2691 bp. The protein expression
levels of TRAIL and TRAIL-2A-HN were detected with
western blotting (Figure 5). The bands corresponding to
TRAIL and TRAIL-2A-HN appeared at 34 kDa and
62 kDa, respectively.Influence of recombinant adenoviruses on the growth of
MSB-1 tumor cells
MSB-1 cells were infected with recombinant adenovi-
ruses Ad-TRAIL, Ad-HN, or Ad-TRAIL-2A-HN. After
48 h, apoptosis was assayed and changes in morphology
were observed using an inverted fluorescence microscope.
After infection with Ad-TRAIL, Ad-HN, and Ad-TRAIL-
2A-HN, MSB-1 cells showed obvious cellular lesions, such
as floating and swelling (Figure 6).
The MTT cell viability assay (Figure 7) showed that
Ad-TRAIL, Ad-HN, and Ad-TRAIL-2A-HN inhibited
the growth of MSB-1 cells. Ad-TRAIL-2A-HN had the
strongest inhibitory effect (P < 0.01); Ad-TRAIL had a
stable inhibitory effect that was weaker than that of the
other viruses (P < 0.01), and Ad-HN showed a moderate
inhibitory effect that showed large variation over the
duration of the infection (1–7 days) (P > 0.05). Thus,
when allowed the same duration of action, the inhibitory
effects of the recombinant adenovirus Ad-TRAIL-2A-
HN on the growth rate of MSB-1 cells was stronger than
that of Ad-TRAIL and Ad-HN.
Figure 3 AD293 cells transfected with recombinant adenoviral plasmids. A: Normal control AD293 cells; B: AD293 cells transfected with
recombinant adenoviral plasmids (Ad); C: AD293 cells transfected with Ad-GFP (observation in normal light); D: AD293 cells transfected with
Ad-GFP (observation in fluorescent light). Pictures were taken at 100x magnification.
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After the MSB-1 cells were infected with recombinant
adenoviruses, the cells were assayed using the Annexin
V FITC/PI kit and flow cytometry, and results are shown
in Figure 8. The recombinant adenoviruses accelerated
MSB-1 cell apoptosis. The apoptotic rates produced by
Ad-TRAIL-2A-HN, Ad-TRAIL, and Ad-HN were 11.61%,
10.60%, and 10.15%, respectively.
Discussion
Previous reports on the anti-tumor effects of TRAIL or
HN have focused on apoptosis induced by either gene
alone. In this article, the ability of TRAIL to target tumor
cells and the induction of apoptosis by HN were utilized
in combination by creating an Ad-TRAIL-2A-HN fusion
gene expressing both proteins. Our results indicated that
the recombinant adenovirus Ad-TRAIL-2A-HN could be
expressed in cell culture, where it inhibited the growth of
the MSB-1 Marek’s disease tumor cell line and induced
apoptosis. Thus, the results of this study suggest that a re-
combinant adenovirus expressing a fusion protein of
TRAIL and HN produced synergistic inhibition of MSB-1
tumor cells.
TRAIL was first cloned from human peripheral blood
lymphocyte cDNA libraries and human heart tissue by
Wiley, who also identified its activity [5]. The full length
TRAIL gene of the chicken is 1134 bp, and its 912 bp
open reading frame has 54.4% homology to that of thehuman homolog. The extracellular region of TRAIL
(894–1134 bp) can effectively inhibit the formation and
growth of multiple tumors. In the chicken, TRAIL is
highly expressed in the spleen and the mononuclear
macrophage system [7]. TRAIL is a member of the
tumor necrosis factor (TNF) family, and plays an im-
portant role in cell proliferation and the induction of
tumor cell apoptosis. TRAIL can bind to certain death
receptors to trigger apoptotic signal transduction path-
ways and induce tumor cell apoptosis, but it has no ob-
vious toxicity or side effects on normal tissues and cells
[13-16]. The combined use of TRAIL with chemother-
apy, radiotherapy, and proteasome inhibitors can en-
hance the sensitivity of tumor cells to TRAIL, and thus
produce synergistic therapeutic effects against tumor
cells. Therefore, the combined use TRAIL with other
therapeutic strategies is a promising strategy for anti-
tumor therapy [17,18].
The Newcastle disease virus (NDV) HN gene possesses
the activities of both hemagglutinin (HA) and neuraminid-
ase (NA). HA enables the virus to adsorb onto the cellular
surface and prevents the self-agglomeration of subse-
quently produced viral particles. NA can hydrolyze sialic
acid on the surfaces of host cells to decompose and destroy
the receptor. In this way the recognition sites of host cells
are exposed, thereby inducing the release of new virus par-
ticles from the infected cell membrane. Therefore, in
addition to promoting viral adsorption onto tumor cells
Figure 4 RT-PCR results for recombinant adenoviral plasmids.
M1: DL5000 DNA Marker; 1: TRAIL gene; 2: HN gene; 3:
TRAIL-2A-HN gene.
Figure 5 Protein abundance of TRAIL and TRAIL-2A-HN.
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alic acid, both on the host cell surface and on the sugar
chain terminal on the viral particle surface, preventing ag-
glomeration of viral particles on the host cells. Moreover,
HN can promote tumor cell adhesion and immunogen-
icity, which can be recognized by the immune system.
In the immune system, most cells can express TRAIL.
After stimulation by type-I interferon IFN-α and type-IIinterferon IFN-γ, TRAIL expression can be detected in
mononuclear macrophages and dendritic cells. Inter-
feron expression is up-regulated in response to viral in-
fection, which induces TRAIL expression [19,20]. In vivo
experiments indicated that IFN-γ increased TRAIL ex-
pression in natural killer (NK) cells from the rat liver,
and thus enhanced the cytotoxicity of NK cells and
inhibited the metastasis of tumor cells to the liver [21].
Inactive NDV can also increase the secretion of IFN-α
by human peripheral blood monocytes and up-regulate
TRAIL expression on the surface of monocytes. How-
ever, monoclonal antibodies against HN prevent this ef-
fect. Furthermore, by up-regulating the apoptotic ligands
of relevant effector cells, HN induces apoptosis in tumor
cells [22].
Because TRAIL can selectively induce the apoptosis of
tumor cells and has no obvious toxicity to normal cells,
recombinant TRAIL represents a potential clinical carci-
nostatic agent. The structure, inhibitory mechanism, and
biological function of TRAIL have been studied with dif-
ferent methods in many laboratories. However, the se-
lective apoptotic effect of TRAIL on tumor cells in
comparison to normal cells is not well understood.
Therefore, we are both optimistic and cautious with re-
gard to the clinical application of TRAIL.
The administration of NDV to humans will inevitably
cause the production of antibodies, and brings the risk
of infection and viral diffusion. Moreover, its non-
effective components may induce allergic reactions.
Therefore, future studies should identify the precise
anti-tumor mechanism of HN and develop genetically
engineered antineoplastic agents.
In this experiment, the HN gene of the NDV was used
to induce apoptosis. HN from NDV was cloned, and the
expression product of the recombinant gene was used in
place of the whole virus. Thus, the side effects caused by
intact viruses, including infection of the organism, were
avoided, and the possibility of viral diffusion was pre-
cluded. The constructed TRAIL-2A-HN fusion gene
combined the apoptosis-inducing function of TRAIL
and the adsorptive capacity of HN from NDV for tumor
cells, and the capacity of the recombinant adenovirus
Figure 6 Apoptosis of MSB-1 cells induced by the recombinant adenovirus. A: Normal MSB-1 cell; B: MSB-1 cell infected by the recombinant
adenovirus (observation in normal light); C: FITC staining of MSB-1 cell undergoing apoptosis; D: PI staining of MSB-1 cell undergoing apoptosis.
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was reported. These results provide a basis for future
in vivo tumor suppression studies using recombinant
adenoviruses.Methods
Amplification of the TRAIL-2A-HN gene
Primer design
Two pairs of primers were designed for RT-PCR amplifi-
cation according to the TRAIL sequence of the chicken
(GI:45383401) and the HN cDNA sequence of NDVFigure 7 Inhibitory effect of recombinant adenovirus on MSB-1
cells. Tumor cells were infected with Ad-TRAIL, Ad-HN, and Ad- TRAIL-
2A-HN at 1 MOI. Cell viability was determined using the MTT assay at
the indicated time.(GI:124295088) in GeneBank. Based on the sequencing
results of the site-directed mutagenesis and fusion genes,
the primers were designed as shown in Table 1 and syn-
thesized by Sangon Biotech Co. Ltd. (Shanghai, China).Amplification of the TRAIL gene Specific-pathogen-
free (SPF) chickens were chosen for the harvesting of
lymphocytes, from which total RNA was extracted with
Trizol reagent. The primers TRAIL-F and TRAIL-R (see
Table 1) were employed to conduct one-step amplifica-
tion of the TRAIL gene based on the instructions for the
TaKaRa One Step RNA PCR kit (AMV). The sequencing
was performed by Sangon Biotech (Shanghai, China).
The recombinant plasmid was named pMD-TRAIL after
verification.Amplification of the HN gene
The lyophilized LaSota strain was dissolved in sterilized
physiological saline. After treatment with penicillin and
streptomycin, the strains were injected into SPF chicken
embryos. Incubation was conducted at 37°C, and the
embryos were collected after 4–7 d. The embryos were
placed at 4°C for 12 h, and then allantoic fluid was col-
lected from the chicken embryo for extraction of total
RNA. As with TRAIL, T-A cloning was employed to
amplify the HN gene using the HN-F and HN-R primers
(see Table 1). The verified recombinant plasmid was
named pMD-HN.
Figure 8 Flow cytometry of MSB-1 cells infected by the recombinant adenovirus. A: Test area has been defined before started the assay; B:
Normal MSB-1 cells without treating adenovirus as a negative control; C: MSB-1 cells were treated with Ad-TRAIL, the apoptotic rates produced
by Ad-TRAIL was 10.60%; D: MSB-1 cells were treated with Ad-HN, the apoptotic rates produced by Ad-TRAIL was 10.15%; E: MSB-1 cells were
treated with Ad-TRAIL-HN, the apoptotic rates produced by Ad-TRAIL was 11.61%.























The bold italics denote KpnI and XhoI enzyme cleavage sites; the italics
denotes the site-directed mutagenesis of the enzyme cleavage sites PacI; the
bold sequence denotes the 2A connecting peptide.
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Site-directed mutagenesis of the TRAIL gene
Analysis of the sequencing results for the TRAIL recombin-
ant plasmid showed that the TRAIL gene contained a PacI
enzyme cleavage site, which is indispensable for the con-
struction of an adenovirus vector. Therefore, the TRAIL se-
quence was modified (TTAATTAA to TTGATCAA) with
gene splicing by overlap extension (SOE). The pMD-
TRAIL recombinant plasmid was used as a template to
amplify the two fragments of the mutated TRAIL gene
using two pairs of primers, CMVtrF +CMVtrMR and
CMVtrMF + CMVtrR (see Table 1). Reaction system
(25 μL): 2.5 μL 10x Pfu Buffer, 2.5 μL MgSO4, 0.5 μL d
NTPs, 1.0 μL primers (0.5 μL each), 1.5 μL template,
0.5 μL Pfu DNA polymerase, and 16.5 μL ddH2O. Reaction
conditions: 95°C for 4 min; 30 cycles of 95°C for 30 s, 58°C
for 30 s, and 72°C for 1 min; and 72°C for 10 min; followed
by gel recovery.
The mutated TRAIL gene was amplified using the
purified upstream and downstream TRAIL fragments
mentioned above as templates and the CMV trF and
CMV trR primers. Reaction system (75 μL): 10 μL
MgCl2 (15 mmol/L), 2.0 μL dNTPs in 10x PCR Buffer,
4.0 μL each of the upstream and downstream templates,
1 μL long PCR enzyme mix, and 54 μL H2O. Reaction
conditions: 94°C for 3 min, 95°C for 20 s, 58°C for 30 s,
and 68°C for 1 min, for 10 cycles. After adding 2 μL
CMVtrF, 2 μL CMVtrR, and 1 μL long PCR enzyme
mix, further amplification was conducted under the fol-
lowing conditions: 94°C for 20 s, 58°C for 30 s, and 68°C
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for 10 min. The gel was recovered and purified.
Amplification of the TRAIL-2A-HN fusion gene
The purified products of the mutated TRAIL fragment
were used as a template to amplify TRAIL-2A with the
primers CMV trF and 2AR. pMD-HN was used as a
template to amplify 2A-HN with the primers 2AF and
CMV hnR. The purified TRAIL-2A and 2A-HN were
used as templates to amplify TRAIL-2A-HN with the
primers CMV trF and CMV hnR. The reaction system
and conditions were based on those mentioned above.
Construction of recombinant adenovirus plasmid
pAd-TRAIL-2A-HN
Construction of recombinant shuttle vector TRAIL-2A-HN
After the separate double restriction-enzyme digestion by
KpnI and XhoI, the recovered TRAIL-2A-HN and pShuttle-
CMV were connected with T4 DNA ligase at 16°C
overnight, and thus the recombinant plasmid pShuttle-
CMV-TRAIL-2A-HN was constructed. pShuttle-CMV-
TRAIL and pShuttle-CMV-HN were constructed with
the same method.
Construction of recombinant adenovirus plasmid
The plasmids pShuttle-TRAIL-2A-HN and pAdEasy-1
were linearized by the PmeI enzyme digestion and
jointly used to transform BJ5183 competent cells. The
colonies were screened by PCR of bacteria liquid and
identified by PacI enzyme digestion. The positively iden-
tified plasmid was named pAd-TRAIL-2A-HN. The re-
combinant adenovirus plasmids pAd-TRAIL, pAd-HN,
and pAd-GFP were constructed using the same method.
Construction and identification of recombinant adenoviruses
Ad-TRAIL-2A-HN, Ad-TRAIL, Ad-HN and Ad-GFP
The recombinant adenovirus plasmid pAd-TRAIL-2A-
HN was extracted using the Hispeed Plasmid Purification
Kit (Qiagen, Venlo, Netherlands) and digested with PacI
enzyme. Lipofectamine 2000 (Invitrogen, Shanghai, China)
was employed to transfect the AD293 cells according to
the manufacturer’s instructions, and the recombinant
adenovirus was obtained after packaging. The mRNA
transcription of target genes was detected by RT-PCR,
and packaging was performed to acquire the recom-
binant adenoviruses Ad-TRAIL, Ad-HN, and Ad-GFP.
Cell transfection was measured by Ad-GFP using a
fluorescence microscope. The viruses amplified at an
early stage were purified with CsCl density gradient
centrifugation. The titration assay for the virus was
carried out with the Ad EasyTM XL Adenovirus Vector
System (Stratagene, Shanghai, China) according to the
manufacturer’s instructions.Cell culture
AD293 cell culture
AD293 cells (1 mL) were added to a 25 cm2 culture flask
(5 × 105 cells/mL), and fresh DMEM culture medium
(10% FBS and 1xpenicillin-streptomycin) was added to
5 mL. The culture was conducted at 37°C with a 5%
CO2 atmosphere and 85% humidity. During passage, the
cells were rinsed with 3 mL PBS buffer (room temperature)
twice. Digestion was conducted with 0.25% trypsin solution
at 37°C for 2–3 min and terminated with 3 mL DMEM
culture solution (10% FBS).
MDCC-MSB-1 cell culture
MSB-1 cells (1 mL) were added to a 25 cm2 culture flask
(5 × 105 cells/mL) and fresh 1640 culture solution (15%
FBS and 1x double antibody) was added to 5 mL. The
culture was conducted at 37°C, 5% CO2, and 85% hu-
midity. During passage, the cells were rinsed with 3 mL
PBS buffer (room temperature) once; after centrifugation
at 1000 g for 5 min, the cells were cultured in 1640 cul-
ture solution.
In-vitro expression detection of recombinant adenovirus
RT-PCR detection
After MSB-1 cells were transfected by recombinant ade-
noviruses for 48 h, total RNA of MSB-1 cells was ex-
tracted. RT-PCR was conducted to detect the target
genes TRAIL-2A-HN, TRAIL, and HN. The reaction
condition and system were as previously described for
RT-PCR.
Western blotting
Cultured MSB-1 cells were infected with the recombin-
ant adenoviruses at 100 multiplicity of infection (MOI).
The Ad-TRAIL group, Ad-HN group, Ad-TRAIL-2A-
HN group, and control group (Ad-GFP) were cultured
in an incubator with a 5% CO2 atmosphere at 37°C for
48 h, and then the following procedures were performed:
protein extraction; SDS-PAGE electrophoresis; protein
transfer to a nitrocellulose membrane; blocking of the
membrane; dilution of TRAIL and HN antibodies with
the sealing solution at a ratio of 1:500; washing the
membrane with PBS; reaction with the enzyme-labeled
secondary antibody; DAB color development; and pho-
tography and recording.
Evaluation of apoptosis in MSB-1 cells mediated by
recombinant adenovirus
MTT assay for cell viability
The recombinant adenoviruses were added to the 96-well
plate lined with MSB-1 cells at 1 MOI, and cultured at 37°C
for 48 h. The cells were treated according to the manufac-
turer’s instructions., and the optical density at 490 nm was
detected with ELISA to determine cell viability.
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The recombinant adenoviruses were added to the 96-
well plate lined with MSB-1 cells at 1 MOI, and cultured
at 37°C for 48 h. Next, the cells were treated according
to the instructions of the FITC Annexin V Apoptosis
Detection Kit I (Becton Dickinson, Shanghai, China).
First, 1–5 × 105 MSB-1 cells, 5 μL Annexin V-FITC, and
5 μL PI (propidium iodide) were added to 1x binding
buffer. The reaction was performed in the dark at room
temperature for 5–15 min, and flow cytometry was con-
ducted. After the cells were stained with Annexin V-FITC/
PI, a drop of the cell suspension was applied to a glass
slide. Finally, staining of the cells was observed with a
fluorescence microscope.
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